Bazinaprine Explained

Bazinaprine (SR-95,191) is an experimental drug candidate. It is a monoamine oxidase inhibitor (MAOI) which is believed to be useful for the treatment of depression. The drug strongly inhibits type A monoamine oxidase, but only weakly inhibits type B. The effects of the drug are reversible in vivo, but not in vitro.^[1] In studies, the chemical has been shown to not interact in vivo with other neurotransmitter or drug receptor sites.^[2]

See also

• Reversible inhibitor of MAO-A (RIMA)

Notes and References

1. Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K . Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro . Journal of Neurochemistry . 50 . 4 . 1137–44 . April 1988 . 3346672 . 10.1111/j.1471-4159.1988.tb10584.x . 12521641 .
2. Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K . SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition . The Journal of Pharmacology and Experimental Therapeutics . 240 . 1 . 251–8 . January 1987 . 3100771 .